Back to top

H.C. Wainwright Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD)

H.C. Wainwright analyst Ananda Ghosh reiterated a Buy rating on ACADIA Pharmaceuticals on July 7 and set a price target of $27.00. The company’s sh...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

ACADIA Pharmaceuticals Inc. (ACAD)